4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.
4SC's current product pipeline includes two programs in clinical development: resminostat and domatinostat.
4SC's goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.
Fraunhoferstraße 22, 82152 Planegg-Martinsried – Germany
Dec. 15, 2005Designated Sponsor(s)
Stifel Europe Bank AGStock exchange(s)
Frankfurt Stock Exchange